Profile data is unavailable for this security.
About the company
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
- Revenue in HKD (TTM)38.86bn
- Net income in HKD535.73m
- Incorporated2025
- Employees11.00k
- LocationBeOne Medicines AGc/o BeOne Medicines I GmbHAeschengraben 27BASEL 4051SwitzerlandCHE
- Phone+41 616851900
- Websitehttps://beonemedicines.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PharmaEssentia Corp | 3.44bn | 1.20bn | 68.58bn | 131.00 | 55.97 | 8.12 | 53.00 | 19.92 | 12.95 | 12.95 | 37.25 | 89.26 | 0.4345 | 1.23 | 4.84 | -- | 15.11 | -5.26 | 16.67 | -5.99 | 89.17 | 82.30 | 34.78 | -19.83 | 6.54 | 64.89 | 0.0291 | -- | 90.67 | 99.81 | 575.37 | -- | 40.94 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.70bn | -817.00m | 96.21bn | 1.87k | -- | 16.96 | -- | 56.67 | -3.65 | -3.65 | 7.53 | 24.33 | 0.3067 | 4.93 | 13.37 | 924,201.40 | -14.76 | -- | -17.11 | -- | 57.10 | -- | -48.12 | -- | 6.32 | -- | 0.0255 | -- | 25.48 | -- | 53.54 | -- | -- | -- |
| Akeso Inc | 2.84bn | -957.10m | 96.90bn | 3.53k | -- | 12.97 | -- | 34.12 | -1.08 | -1.08 | 3.24 | 8.11 | 0.2115 | 0.7726 | 3.95 | 935,890.60 | -7.07 | -8.38 | -8.20 | -9.82 | 79.26 | -- | -33.46 | -33.18 | 4.01 | -536.98 | 0.4168 | -- | -53.08 | 97.39 | -125.37 | -- | 34.14 | -- |
| WuXi Biologics (Cayman) Inc | 22.69bn | 4.75bn | 167.57bn | 12.55k | 36.21 | 3.24 | 22.27 | 7.39 | 1.12 | 1.12 | 5.41 | 12.50 | 0.3442 | 6.36 | 3.06 | 1,804,194.00 | 8.45 | 7.98 | 10.57 | 9.95 | 42.65 | 42.71 | 24.54 | 25.82 | 2.69 | -- | 0.0943 | 0.00 | 9.63 | 36.21 | -1.28 | 27.05 | 3.97 | -- |
| BeOne Medicines AG | 38.86bn | 535.73m | 329.79bn | 11.00k | 657.68 | 9.17 | 187.97 | 8.49 | 0.3129 | 0.3129 | 26.85 | 22.44 | 0.7387 | 1.43 | 6.94 | -- | 1.02 | -22.00 | 1.51 | -28.96 | 86.19 | 83.69 | 1.38 | -72.20 | 2.17 | -- | 0.308 | -- | 54.96 | 54.83 | 26.87 | -- | 27.25 | -- |
| WuXi AppTec Co Ltd | 50.22bn | 16.96bn | 349.45bn | 39.41k | 19.48 | 4.11 | -- | 6.96 | 5.23 | 5.23 | 15.49 | 24.80 | 0.5259 | 3.70 | 4.82 | 1,126,406.00 | 17.97 | 12.32 | 22.39 | 15.68 | 45.00 | 39.12 | 34.17 | 22.92 | 2.36 | -- | 0.0983 | 30.00 | -2.73 | 24.97 | -1.63 | 38.50 | 9.60 | 37.38 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (International Investors)as of 09 Sep 2025 | 69.24m | 4.49% |
| HHLR Advisors Ltd.as of 13 May 2025 | 55.10m | 3.58% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 30.58m | 1.98% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 22.99m | 1.49% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 19.09m | 1.24% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 9.73m | 0.63% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 9.53m | 0.62% |
| Baillie Gifford & Co.as of 31 Jan 2026 | 8.46m | 0.55% |
| T. Rowe Price Associates, Inc. (IM)as of 05 Feb 2026 | 7.91m | 0.51% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 7.22m | 0.47% |
